Oragenics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on July 30, 2010, regarding events occurring on that date. The Company is a Florida corporation headquartered in Jacksonville, Florida. The filing details the closing of a previously announced Common Stock Purchase Agreement and the establishment of a new credit facility with the Koski Family Limited Partnership (KFLP), the Company's largest shareholder.
Key Financial Metrics and Transactions
- Capital Raised: The Company received $1,000,000 in cash.
- Debt Reduction: A $1,000,000 outstanding promissory note issued to KFLP was cancelled and exchanged for equity.
- Equity Issuance: 5.0 million shares of Common Stock were issued to KFLP at a price of $0.40 per share.
- Total Consideration: $2.0 million aggregate value ($1.0 million cash + $1.0 million debt conversion).
- New Credit Facility: An unsecured revolving credit line of up to $2.0 million was established with KFLP.
- Interest Rate: LIBOR plus 6.0%.
- Term: Twelve months, commencing August 1, 2010.
- Drawdown Status: As of the filing date, no funds have been drawn on the new Credit Facility.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements or period-over-period revenue and profit metrics. The primary material change is the reduction of $1.0 million in secured debt and the increase in outstanding common shares by 5.0 million. Additionally, accrued interest on the cancelled note was waived by the KFLP.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue projections, or management commentary on future operations. The ability to access the new $2.0 million Credit Facility is subject to specific conditions, including the receipt of a certificate of no adverse change from the Company and compliance with the facility terms. The equity issuance was conducted under Section 4(2) of the Securities Act of 1933 as a private placement.
Key Facts for Investor Verification
- Verify the dilution impact of the 5.0 million new shares on existing shareholders.
- Confirm the current status of the $2.0 million revolving credit facility and whether any drawdowns have occurred since August 1, 2010.
- Review the terms of the "certificate of no adverse change" required to access the credit line.
- Assess the relationship and voting power of KFLP as the largest shareholder following this transaction.